UBS raised the firm’s price target on LifeStance (LFST) to $10 from $9 and keeps a Buy rating on the shares. LifeStance posted a solid beat across the board for Q3 and raised its fiscal 2025 profit outlook, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- LifeStance Health Group Reports Strong Q3 2025 Results
- LifeStance Health’s Earnings Call: Strong Growth Amid Challenges
- LifeStance Health Reports Strong Q3 2025 Financial Results
- LifeStance reports Q3 revenue $363.8M, consensus $355.03M
- LifeStance backs FY25 revenue view $1.41B-$1.43B, consensus $1.41B